Singapore and Asia’s leading BioPharma Map the Future and Catalyze Recovery for the Biomanufacturing Industry
Singapore, 31st March 2022 – The 9th Annual Biologics Manufacturing Asia 2022 & the 6th Annual BioLogistics World Asia 2022 conferences kicks off with Industry views on post pandemic biomanufacturing and a focus on the future of Asia’s Bioprocessing sector. The annual event gathered biologics and vaccine experts from all over the world at Suntec Convention Center from 29th to 31st March 2022. Over 1,000+ participants and 400+ companies attended from 50 countries, representing more than 50% of the world’s top manufacturers of biologics.
The conference presents thought leaders the opportunity to exchange views on the optimism in Asia Pacific’s biologics & vaccine manufacturing and biologistics projected growth and how industry players can link arms to build a better future as well as scaling up the next wave of innovation.
The Biomedical Manufacturing industry in Singapore constituted 4% of Singapore’s GDP with a potential for growth as we prepare for future pandemics. By bringing key stakeholders together in Singapore, a knowledge exchange such as this can spur investment and job growth in the BioPharma space, said Sumukhi Sreevatsan, General Manager, IMAPAC Singapore. We are proud to facilitate critical conversations, strategic partnerships and new ideas for today’s challenges and opportunities in biomanufacturing that will enhance speed and quality in reduced time for biologics and vaccine manufacturing, she added.
Amid all the uncertainties, the biopharma industry has faced disruptions of its own. In the biologicals and vaccine development space, there are significant opportunities, but with those opportunities come several challenges: best practices in upstream processing, cost-reduction in downstream processing, single-use technologies, and supply chain management, all of which deserve attention from those who are most knowledgeable about this field.
“It was great to attend a conference in person after two years. I really enjoyed the topics that were discussed and the Q&A sessions were very productive as well. The IMAPAC team handled the mix of virtual and online attendees very well making the conference a great overall experience” quoted Executive Director, Amgen Singapore Manufacturing Ltd.
With two years of severe supply chain disruption and uncertainty at its back, the biopharma logistics profession has come forward with ingenuity to deliver life-critical vaccines, therapies and other products across complicated geographies. In recognition of this, the BioLogistics World Asia conference forefronted several case studies by companies on the front line as well as keynotes from NGOs like UNICEF and GAVI covering the vaccine rollout efforts and analysis.
Several companies came together to present the latest ideas and technologies, including Pfizer, Gilead Sciences, Samsung Biologics, Regeneron, Serum Institute of India, Novartis, Chugai Pharma, Amgen, Astra-Zeneca, GenScript, Merck, Cerecin, and Hetero Labs, that will catalyse this transformation.
Alongside the conferences, the Asia-Pacific Bioprocessing Excellence Awards 2022 kicks off to recognize exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing and biologistics excellence at enhanced speed, reduced cost, and superior quality. Featuring top bioprocessing, biomanufacturing and supply chain leaders in the industry, along with the latest advances in technologies and best practices in manufacturing, the Asia-Pacific Bioprocessing Excellence Awards applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
IMAPAC Pte Ltd started in Singapore in 2010 with providing quality conference and networking opportunities for businesses in the life science industry. As it has expanded its portfolio by venturing into market research reports, webcasts, and digital solutions, it has now become the one-stop solution for business intelligence and networking activities in the life science industry.
Over the past 3 to 5 years IMAPAC has launched multiple new projects and even moved into newer geographies.
IMAPAC on an unrelenting mission to help biopharmaceutical businesses globally generate tangible growth. IMAPAC strives to make the best products because that’s why it was started in the first place. It doesn’t mean “among the best” or even “best at a particular price point.” It simply means to “make the best”, period.
IMAPAC has also launched the market research division in 2019 where we are producing bespoke market Intelligence reports and real-time trackers on the different segments in the Life Science industry. Additionally we have launched our LeadGen 360 digital solutions in aiding the biopharma and life science companies to create brand awareness, generate high quality leads and do top-notch product launches.